Table 1 Characteristics of patients in included studies.

From: Financial toxicity in hematological malignancies: a systematic review

 

n (%)

Percent of subjects with hematologic malignancy

 

 100% of subjects with hematologic malignancies

42 (76.4%)

 >25%, <100% subjects with hematologic malignancies

13 (23.6%)a

Specific cancers represented

 

 Leukemia only

16 (29.1%)

 Lymphoma only

4 (7.3%)

 Multiple myeloma only

5 (9.1%)

 Myeloproliferative neoplasm only

1 (1.8%)

 Multi-disease

29 (52.7%)

BMT or cell therapy

12 (21.8%)

Survivorship, or >5 years out from treatment

8 (14.5%)

Pediatric subjects

16 (29.1%)

Median number of subjects per study

162

Financial toxicity to the caregiver

19 (34.5%)b

Geographic region

 

 North America

29 (52.7%)

 Asia

16 (29.1%)

 Oceania

5 (9.1%)

 Europe

3 (5.5%)

 Africa

1 (1.8%)

  1. aIn these 13 studies (23.6%) the remainder of subjects who did not have a hematologic malignancy represented either solid organ malignancies or a benign hematologic cause for bone marrow transplant.
  2. bOf these 19 studies that assessed financial toxicity to the caregiver, two studies (10.9%) assessed financial toxicity to both the caregiver and the patient, and in three studies (15.7%) the caregiver was for an adult patient.
Back to article page